12:00 AM
 | 
Mar 11, 2013
 |  BC Week In Review  |  Company News  |  Other News

Mission Therapeutics cancer news

Mission received a Biomedical Catalyst Feasibility Award from the U.K.'s Technology Strategy Board to discover deubiquitylating enzyme targets to treat drug-resistant ovarian cancer. The...

Read the full 96 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >